Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effectiveness of a commercial toothpaste that contains a new compound aimed at protecting a balanced oral microbiome in volunteers with periodontitis. This study is controlled and conducted across multiple centers, focusing on participants who regularly receive professional tooth cleaning every 3 to 6 months during periods without active treatment. The study aims to determine how well the toothpaste supports oral hygiene and potentially benefits oral microbial health. Participants will brush their teeth twice daily with the assigned toothpaste over a 3-month period, refraining from mouth rinsing after spitting. The toothpaste includes commonly used ingredients such as sodium fluoride and cleaning agents, along with a novel compound that may promote a healthy oral microbiome. This intervention period takes place between two professional tooth cleaning visits as part of a supportive periodontal therapy regimen. During the study, participants will be monitored for changes in oral health and the effectiveness of the toothpaste from enrollment until the end of the 12-week treatment. Assessments will include evaluation of oral microbial composition and dental health status. Researchers will also ensure participant safety and adherence to study procedures throughout the trial, which is expected to complete by the end of 2026.
Actively Recruiting
Researchers are evaluating whether systematic pelvic and para-aortic lymphadenectomy LNE improves overall survival in patients with stage I or II endometrial cancer who have a high risk of recurrence. The trial also looks at how LNE affects disease-free survival, quality of life, complications, side effects, and the number of lymph nodes removed. A total of 640 patients with specific histological types and stages of endometrial cancer will take part in this study. Participants will be randomly assigned to one of two groups. In Arm A, patients will undergo the standard surgical procedure including total hysterectomy and bilateral salpingo-oophorectomy, with an omentectomy added for certain cancer types. In Arm B, patients will receive the same standard surgery plus systematic pelvic and para-aortic lymphadenectomy reaching up to the left renal vein. The study compares these two surgical approaches. Throughout the study, participants will be monitored for overall survival over 60 months. Researchers will also assess disease-free and disease-specific survival at multiple time points up to five years. Serious complications will be recorded during surgery and follow-up visits. Quality of life will be evaluated regularly using standardized questionnaires. The number of lymph nodes removed will be documented during surgery to support the evaluation of treatment impact and safety.
Actively Recruiting
Researchers are conducting a multi-center, prospective, non-interventional study in Germany to collect real-world clinical and patient-reported data from women with primary advanced FIGO stage III or IV or recurrent endometrial cancer receiving first-line treatment. The study evaluates two maintenance therapies following chemotherapy with Carboplatin, Paclitaxel, and Durvalumab CPD, focusing on outcomes in patients with different tumor DNA mismatch repair statuses. The goal is to understand the effectiveness, safety, and patient experiences with these treatments in routine clinical practice. Participants receive first-line CPD chemotherapy. Those with DNA mismatch repair deficient tumors dMMR cohort receive maintenance therapy with durvalumab alone if their disease is controlled after chemotherapy. Participants with DNA mismatch repair proficient tumors pMMR cohort receive maintenance therapy with durvalumab and olaparib under similar conditions. Treatment decisions are based on standard care guidelines and made jointly by patients and their physicians. The study follows patients over time to observe treatment duration and transitions. During the study, participants complete patient-reported outcome questionnaires to assess quality of life and symptom changes after chemotherapy. Clinical data including time to next treatment and progression-free survival are collected up to 46 months. The study also tracks maintenance therapy duration, chemotherapy duration, and timing between chemotherapy and maintenance start. Safety and treatment use are monitored as part of routine care. Overall, the study provides long-term real-world insights into first-line and maintenance therapy for endometrial cancer.
Actively Recruiting
Researchers are evaluating the effects of NORTASE42, a pancreatic enzyme treatment, compared to standard care in patients who have undergone gastrectomy, which involves removal of part or all of the stomach. The study focuses on how these treatments affect patients quality of life and weight over time. This Phase 3 trial is randomized and double-blinded to compare the two groups fairly. Participants will receive either 10 to 15 capsules of NORTASE42 or a placebo each day for six months. This treatment period allows researchers to assess the impact of the enzyme therapy after gastrectomy. The trial includes patients who had at least 50% of their stomach removed and excludes those with other conditions or treatments that could interfere. During the study, participants will be monitored for various health measures including disease-specific quality of life, weight, nutritional supplementation, blood levels of haemoglobin, proteins, glucose, cholesterol, and vitamins A, B12, D, E, and K. These assessments occur over the six-month treatment period to evaluate how the interventions affect overall health. Safety and compliance are also tracked throughout the trial.